Growth hormone (GH) is important in the development and maintenance of bone; however, the IGF-dependent and -independent molecular pathways involved remain to be established. We used microarray analysis to evaluate GH signaling pathways in four week old GH-deficient mice following a single injection of GH (4 mg/kg body wt) or PBS (n = 6/group) at 6 or 24 hours after treatment. 6,160 genes were differentially expressed at P ≤ 0.05, and 17% of these genes were identified at both time points. Several of the genes differentially expressed were ESTs and the remaining genes fell into 49 GO categories. For subsequent studies, we focused on T-box (Tbx) 3, a novel transcription factor, which increased > 2 fold at both time points. Real-time reverse transcriptase (RT)-PCR analysis determined that pre-treatment with
Introduction
Growth hormone (GH) is important in the development and maintenance of bone. This has been demonstrated in several experiments utilizing human and animal models that are GH deficient and/or treated with GH. In GH deficient adults, decreased bone mineral density (BMD) can be corrected with exogenous GH treatment (20, 38) . In addition, GH treatment increases bone formation markers as well as serum concentrations of IGF-I (14, 19, 38) . We and others have demonstrated that mice deficient in GH production or action exhibit significant deficits in body weight, femur length, and volumetric (v) BMD (27, 42) . It is well known that GH may act directly on specific tissues or by binding to its receptors and stimulating the release of IGF-I.
When GH binds to its receptors, JAK is phosphorylated and several pathways, including STAT, MAPK, and phosphoinosital-3 kinase (PI3K), are activated (16, 31) . Through these pathways, GH regulates the transcription of specific genes, such as IGF-I. Recent evidence has demonstrated that GH may also act independently of IGF-I in bone. In a previous study, we reported that the rate of gain in femur length and periosteal circumference during the postpubertal growth period are impaired to a greater extent in GH deficient lit/lit mice compared to IGF-I knockout mice (27) . Furthermore, previous published work has suggested an involvement of IGF-independent effects of GH in stimulating growth (21, 35, 42) . However, the molecular pathways by which GH exerts its anabolic effects in bone remain to be established. Therefore, our first objective was to identify genes in bone that are acutely regulated by GH treatment through the use of whole genome microarray analysis. To meet our objective, we evaluated the effect of a single effective dose of GH using the GH-deficient, lit/lit mouse model. This model is characterized as a dwarf mouse with a missense mutation of the GH releasing hormone receptor (GHRHR) and no detectable concentrations of GH (3, 9, 13, 17, 27) , therefore it provides a sensitive model for examining the effects of GH on target genes in bone. Our second objective was to further characterize specific genes identified by microarray analysis in mediating GH effects in bone. Specifically, we examined the role of a novel transcription factor, T-box (Tbx) 3, in regulating osteoblast proliferation in vitro. In general, we determined that several thousand genes are acutely regulated by a single injection of GH in bone and that Tbx3 is an important regulator of osteoblast proliferation.
Materials and Methods
Animals: C57BL/6J-Ghrhr<lit> [GHRHR gene disruption, allele name little (lit/lit)] mice were purchased from The Jackson Laboratories (Bar Harbor, ME). The lit/lit mouse is a dwarf mouse strain characterized by no detectable concentrations of circulating GH and, as a consequence, low serum IGF-I concentrations caused by a missense mutation in the GHRHR gene that abolishes the function of the receptor (9, 17) . At four weeks of age, twenty-four mice were treated with a single injection of human (h) GH [4 mg/kg body weight; a kind gift from Biosidus Co. (Buones Aires, Argentina); n = 12] or PBS (n = 12) by subcutaneous injection. The dose was selected based on our previous findings that daily injections of GH (4mg/kg body weight) in lit/lit mice induced circulating concentrations of IGF-I to those of wild-type mice (23) . At 6 (n = 6 GH injected; n = 6 PBS injected) or 24 (n = 6 GH injected; n = 6 PBS injected) hours after the single injection of GH, mice were euthanized by CO 2 inhalation, followed by decapitation.
Femur, muscle, tibia, and liver were removed and immediately stored in liquid nitrogen and then at -70° C until analyzed.
The experimental procedures performed in this study were in compliance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Animal Studies Subcommittee at the Jerry L. Pettis Memorial Veteran Affairs Medical Center.
RNA Extraction: RNA was extracted from the bone, muscle, and liver of each mouse (n = 6/group) using Trizol (Invitrogen, Carlsbad, CA) and an RNeasy Mini Kit (Qiagen Inc., Valencia, CA). Briefly, frozen tissues samples were ground with a mortar and pestle with 1 mL of Trizol until a thin powder was visible. RNA was then extracted using the RNeasy Mini Kit according to the manufacturer's instructions. Following extraction, up to 10µg of RNA was DNase treated with a DNA-free kit (Ambion, Austin, TX) to remove any residual DNA. RNA quality was determined using a 2100 Bioanalyzer (Agilent, Palo Alto, CA) and RNA was quantified using a NanoDrop Spectrophotometer (Wilmington, DE).
Microarray Analysis: Within each treatment group, RNA from two animals were pooled together for a total of 3 replicates per treatment group. 500 ng of total bone RNA from each pooled sample (N = 12) was reverse transcribed and linear amplified using a primer containing oligo (dT) and a T7 RNA polymerase promoter. After synthesis of the first and second strands of cDNA, the product was used in an in vitro transcription reaction to generate cRNA in the presence of cyanine 3-or cyanine 5-labeled UTP. The labeled cRNA was purified using RNeasy spin columns (Qiagen) to remove free nucleotides. Two micrograms of fragmented cyanine 3-labeled cRNA of control sample was mixed with equal amounts of cyanine 5-labeled cRNA of GH treated sample, and the mixtures were hybridized to 22K mouse development oligo microarrays (Agilent, Palo Alto, CA) for 17 hours at 60°C with constant rotation. The slide was then washed in sodium, saline citrate (SSC) buffer, and dried with pressurized nitrogen. All slides were scanned using an Agilent DNA Microarray scanner and the images were processed and analyzed using Agilent feature extraction software. Expression analysis of the data was analyzed using GeneSpring 7.0 (Silicon Genetics, Redwood City, CA). with α-MEM containing 10% calf serum, 100 U/mL penicillin, and 100 µg/mL streptomycin.
Gene Expression
Culture media were changed every two days until 75% confluency was reached (after approximately 6 days), and then 50 µg/mL ascorbic acid and 10 mM β-glycerophosphate were added to the media to induce differentiation into osteoblast cells which was confirmed by nodule formation. Half of the culture media were changed every three days for 24 days. Cells were extracted with Trizol at days 0, 6, 12, 18, and 24 and stored at -70° C until RNA extraction was performed using an RNeasy Mini-kit (Qiagen) according to the manufacturer's protocol.
Regulation of Tbx3 expression in MC3T3-E1:
For all in vitro experiments, MC3T3-E1 cells, a mouse osteoblast-like cell line, were cultured in DMEM or α-MEM containing 10% calf serum (CS) or fetal bovine serum (FBS) until 70% confluency. Media were changed to serum-free two times over a 24 hour period. Cells were treated with GH (100 ng/mL), IGF-I (30 ng/mL), IGFBP-4 (300 ng/mL), TNF-α (20 ng/mL), BMP-7 (30ng/mL), or Wnt3a (1nM) for 24 hours.
RNA was extracted from the cells using an RNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. Qiagen, which was used to optimize transfection conditions. MC3T3-E1 cells were transfected with siRNA-1, -2, and -NC using RNAiFect (Qiagen) according to the manufacturer's directions.
Briefly, cells were plated in α-or D-MEM containing 10% CS or FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin until 70% confluent. Cells were passaged with 1x Trypsin and plated at a density of 3,000 cells per well for 96-well plates and 50,000 cells per well for 24-well plates.
Cells were allowed to adhere to the plate (24 hours) and transfected with 100 nM siRNA plus Thymidine was added to each well and incubated for 6 to 8 hours. Cells were washed with PBS and removed by swabbing with 10% TCA. Swabs were washed with TCA and 95% ETOH and counts were determined using a scintillation counter (26) .
Apoptosis: MC3T3-E1 cells were transfected and grown as described for the alamarBlue assay.
Apoptosis was determined using an Apo-ONE Homogeneous Caspase-3/7 Assay (Promega, Madison, WI). Total protein was determined by the Bradford assay (Bio-Rad, Hercules, CA).
Statistical Analysis: Microarray data were analyzed using GeneSpring 7.0 (Silicon Genetics).
Local background-subtracted median signal intensities were used as intensity measures and the data were normalized using LOWESS normalization (Workman et al., 2002). The genes which had a raw signal of 100 or greater and passed with flag value "present" were included in the analysis. To minimize the false positive/negative error rate in our microarray, we used a combination of confidence (P ≤ 0.05) and fold change (i.e. ≥ 1.0, 1.5, or 2.0 fold) to restrict our gene lists. For Gene Ontology (GO) analysis we used MappFinder (10) . In this analysis, we used the genes that were significantly up-regulated (fold change > 1; P < 0.05) and significantly down-regulated (fold change < 1, P < 0.05) based on GeneSpring analysis. The Z score was set at > 0 and the permutated P at < 0.05. To eliminate redundant minor GO categories, we set both the minimum number of changed genes and the minimum number of measured genes to 3. Upor down-regulation of GH/IGF axis factors were used to confirm the effectiveness of the single GH injection to alter gene expression identified by microarray analysis (Table 3 ). The current experimental design and analysis are compliant with current MIAME guidelines (4) , and the data are available in the NCBI database (Accession number: GSE3689). Real-time RT-PCR and cell number data were analyzed using Student's T-Test. Osteoblast time course data were analyzed using ANOVA (Statistica Software). A significant difference was determined at P ≤ 0.05.
Results

Microarray Analysis
We identified 19,081 genes on the microarray chips that were expressed at an intensity of 100 or greater. Thirty-two percent (6,160) of these genes were differentially expressed at P ≤ 0.05 at 6 and/or 24 hours (Supplemental table 1 ) and the number of genes identified at each time point that fit these criteria are listed in Table 1 . Overall, a greater number of genes were upregulated than down-regulated following a single injection of GH and more genes were differentially expressed at 24 than at 6 hours. Interestingly, 17% (1,034) of the 6,160 genes were differentially expressed at both 6 and 24 hours.
To more closely evaluate the large number of genes, , we used three main approaches to organize the data. First, we used GO analysis to categorize genes that were significantly up-or downregulated (P < 0.05). We identified 395 genes that fell into 49 GO categories (Supplement Table   S2 ). Interestingly, more than half the genes differentially expressed by GH were ESTs and therefore, could not be included in the GO analysis.
Secondly, to confirm the effectiveness of the single injection of GH, we identified genes associated with the GH/IGF axis that were up-or down-regulated by GH treatment at P ≤ 0.05 (Table 2) . Specifically, IGF-I and IGFBP-3 were up-regulated greater than 2 and 1.5 fold, respectively, in bone at 6 and 24 hours. In addition, STAT-1, -4, and 5a were down-regulated and STAT-6 was up-regulated at 24 hours. These data indicate that our single dose of GH was effective within 6 hours and triggered negative feedback mechanisms by 24 hours.
Thirdly, we examined all genes to determine if major pathways involved in the regulation of bone were acutely regulated by GH. Using the criteria of genes differentially expressed at P ≤ 0.05, we identified several Wnt signaling genes ( (Table 2) .
Real-time RT-PCR Analysis
To further validate our microarray data, we examined the gene expression of IGF-I in the bones of lit/lit mice by real-time RT-PCR. Similar to the microarray data, IGF-I expression increased (3.4 fold; P ≤ 0.01) at 6 hours following GH treatment (data not shown). For subsequent studies, we focused on Tbx3, a novel transcription factor of which little is known, which was up-regulated 2.2 and 2.5 fold (P ≤ 0.05) at 6 and 24 hours, respectively, in the microarray analysis. It is known that Tbx3 plays an important role in limb development, but to our knowledge, no information is available about its role in mediating GH actions. Real-time
RT-PCR analysis demonstrated that Tbx3 is expressed in bone, muscle, and liver ( Figure 1 ).
Following GH treatment in the lit/lit mice, Tbx3 expression increased 4.1 fold (P ≤ 0.05) at 24 hours in bone and 1.9 fold (P ≤ 0.05) at 6 hours in muscle. In the liver, Tbx3 expression decreased 1.6 fold (P = 0.05) at 24 hours.
Regulation of Tbx3 mRNA expression in mouse pre-osteoblast cells
In MC3T3-E1 cells, GH induced (P ≤ 0. 
Knockdown of Tbx3 expression using siRNA
To determine the optimal conditions and transfection efficiency, cells were transfected with various amounts of a negative control, fluorescently labeled siRNA and RNAiFect To determine the efficiency of knockdown of Tbx3 expression, cells were transfected with 100nM Tbx3 siRNA-1, -2, and siRNA-1 and 2. Based on real-time RT-PCR analysis, we determined that Tbx3 expression was reduced 31 ± 5, 22 ± 5, and 31 ± 2 % with siRNA-1, -2, and the combination, respectively (P < 0.01), compared with RNAiFect alone (data not shown).
Tbx3 is an important mediator of osteoblast proliferation
First, to determine the specificity of the Tbx3 siRNA, we determined, by alamarBlue assay, the response of osteoblast cell number to transfection with the two Tbx3 siRNA (siRNA-1 and -2) and the NC siRNA. A slight reduction (12%) in cell number was observed with the siRNA-negative control (NC), however a greater reduction (32 to 38%) was observed with each Tbx3 siRNA, as well as the combination (P < 0.05; Figure 5 ). Therefore, we concluded that the Tbx3 siRNA were specific to the Tbx3 gene. For further experiments, we used Tbx3 siRNA-1. Thymidine was determined.
A similar response was observed, such that knockdown of Tbx3 reduced [3H] Thymidine incorporation into the DNA (17 to 20 %) in the presence and absence of serum (P < 0.01; data not shown). To determine if the decrease in cell number and DNA synthesis was due to increased apoptosis, we next determined caspase activity. We determined that Tbx3 siRNA did not increase caspase activity, however it does appear to reduce the basal caspase activity in MC3T3-E1 cells (P < 0.001; Figure 6 ).
Discussion
Microarray Analysis
The IGF-dependent and -independent pathways by which GH acts in bone are not well known. Through the use of microarray analysis in a model that is very sensitive to a single injection of GH, we have identified several genes induced by GH of which little information is known. In addition, we have provided evidence that several genes associated with known signaling pathways (i.e. Wnt and BMP) are acutely regulated by GH in bone. Interestingly, we identified a novel transcription factor, Tbx3, which is acutely regulated by GH as well as other growth factors in bone and is an important regulator of osteoblast proliferation.
We have provided the first report of a global analysis of gene expression in bone in response to GH administration in a GH sensitive model. Since our microarray chips included 22,000 genes, and we used the GH deficient lit/lit mouse model, we were not surprised that we identified over 6,100 genes that were acutely regulated by a single injection of GH in bone.
Since more than half of the genes were of an unknown function, or ESTs, we conclude that there are many genes involved in mediating GH actions that have not been identified. Interestingly, several of the ESTs identified include a zinc finger motif, which indicates a potential role for these genes as transcription factors. In addition, proteins encoded by several ESTs contained a proline rich region, which is similar to the GH receptor in which a proline rich region is required for phosphorylation of JAK (32) . Future studies are needed to establish if one or more of these ESTs are important mediators of GH effects in bone.
It is not surprising that more genes were up-regulated than down-regulated at both time points since it has been well established that GH has anabolic effects on several tissues, including bone (29) . For example, GH treatment increases proliferation of osteoblast cells in vitro and increases bone formation in vivo (29) . In addition, many of the effects of GH are mediated by IGF-I. Therefore, the greater number of genes differentially expressed at 24 versus 6 hours was most likely due to activation of genes downstream of GH, such as IGF-I, which in turn stimulates additional genes. However, further analysis is needed to determine which of the genes differentially expressed at six hours in the bones of GH treated mice compared with vehicle treated control mice are the result of direct actions of GH, independent of IGF-I. It should be mentioned that since we used hGH, there is a possibility that some of the differentially expressed genes may be the result of GH acting through the prolactin receptor (43) . However, we evaluated several known downstream targets of prolactin (FGF-2, IRF-1, Bax, Jak2, Tec) (7, 30, 37, 39) , and found no significant change in their expression. Based on these findings, and the findings that expression levels of many genes associated with the GH/IGF axis showed the anticipated change after a single injection of GH, we are confident that the changes observed are in response to GH acting through the GH receptor.
As expected, several genes associated with the GH/IGF axis were acutely regulated by GH. Interestingly, we identified two novel proteins, IGF-2 mRNA-binding protein (IMP)1 and 3, which are members of a family of RNA binding proteins that play a role in post-transcriptional processes (18) . Very little is known about these proteins and only a few target genes have been identified (18) . We observed an increase in IMP1 and a decrease in IMP3 following a single injection of GH. These data are consistent with previous reports that IMP1 is essential for normal embryonic and postnatal development (18) , whereas IMP3 is implicated in the suppression of growth (28). Based on our data and previous reports, we hypothesize that these proteins may be important mediators of GH action in bone.
Examination of all genes differentially expressed at P ≤ 0.05 revealed several signaling genes about which little is known concerning their role in mediating GH effects in any tissue.
Interestingly, several of these genes are from two major pathways, Wnt and BMP, which are important regulators of osteoblast differentiation. Based on our microarray data, it appears that these pathways may be involved in crosstalk with the GH/IGF axis. We observed up-regulation of Wnt5a in bone, which is supported by recent evidence that Wnt5a is produced by osteoblasts (44). In addition, several genes downstream of Wnt (β-catenin, Dvl2, Axin, Csnk2α2, Apc, and Csnk1α1) were up-or down-regulated by GH, providing the first evidence for a role for Wnt signaling genes (canonical and non-canonical pathways) in mediating GH actions in bone.
Interestingly, three genes associating with the BMP pathway, an important regulator of bone formation (25), were down regulated by a single injection of GH. This is in contrast to a previous report in which several injections of GH stimulated BMP-2 and -4 in rats, as well as IGF-I (24) . Although the different observations may be due to the different duration of GH treatment in the two experiments, the significance and mechanisms involved in the decreased expression in BMPs in the current study needs further evaluation. Interestingly, the Madh5 protein, involved in BMP signaling, was up-regulated by GH treatment greater than 2 fold at 24 hours. Our data, combined with recent evidence that interactions between IGF, BMP, and Wnt signaling genes occur (2, 41) , supports the possibility that crosstalk may occur between these major signaling pathways in mediating GH effects in bone. However, since some of the genes identified by these criteria (P ≤ 0.05) only changed by < 1.5 fold, further confirmation of changes in the expression of these genes is needed to confirm the role of these genes in mediating GH action in bone.
Comparison of GH responsive genes identified in bone in this study with those identified in other tissues in previous reports reveals similarities and dissimilarities. Genes with functions related to receptor signaling, membrane trafficking, apoptosis, and metabolism have been reported to be regulated by GH in previous microarray experiments using liver tissue (1, 15), as well as in our study. Specific genes related to these categories that were altered in response to GH in both liver and bone include translocase, IGFBP-2, tubulin-γ, transferrin, Bcl-like apoptosis facilitator, fatty acid CoA ligase, and ribosomal proteins. There are a number of potential explanations for the limited similarity in GH responsive genes between our study and previous studies in the liver. First, there may be species-and tissue-specific differences in the genes that are regulated by GH. Second, GH's effect on target genes may be dependent on the age of the animals. Third, we administered only a single injection of GH and examined the genes that responded 6 to 24 hours after treatment, while in previous studies, multiple injections of GH were administered. Further microarray studies using multiple GH-responsive tissues from the same animals after a single injection are required to determine if GH regulates similar target genes in different tissues.
Regulation of Tbx3 expression
Another interesting finding in this study relates to up-regulation of Tbx3 (a novel transcription factor) at 6 and 24 hours after a single injection of GH, which was confirmed by real-time RT-PCR. Since we were interested in identifying molecular pathways involved in mediating GH action, our initial focus was on the transcription factors. We chose to further investigate Tbx3 because, to our knowledge, these are the first data that suggest an involvement of Tbx3 in mediating GH effects in bone. In addition, we demonstrated that Tbx3 is expressed in several tissues, its response to GH is tissue-specific, and very little information is known about Tbx3 except that: 1) it can act as a regulator of transcription; 2) a mutation of the gene results in ulnar mammary syndrome in humans; and 3) a homozygous mutation of Tbx3 in mice is embryonically lethal (6, 8) .
Through further in vitro analysis, we demonstrated that GH effects on Tbx3 expression in bone may be independent of IGF-I. In this regard, we found that pretreatment of MC3T3-E1 cells with IGFBP-4, a known inhibitor of IGF-I, did not block GH-induced Tbx3 expression. In addition, the abolished GH induction of Tbx3 expression by pretreatment with TNFα, a known inhibitor of STAT5b, indicates that GH may stimulate Tbx3 through the JAK-STAT pathway.
However, further experiments are needed to confirm that this is the primary pathway by which GH regulates Tbx3 expression in bone. In contrast to bone and muscle, GH treatment decreased Tbx3 expression in liver, however the significance of the differential expression of Tbx3 in bone versus liver remains to be established.
Previous experiments have determined that a mutation of the Tbx3 gene in humans results human ulnar mammary syndrome, which is characterized by limb malformation (5). In addition, a homozygous mutation of the Tbx3 gene in mice results in severe limb defects, similar to ulnar mammary syndrome, and is embryonically lethal (8) . Consistent with these data, we demonstrated in vitro that Tbx3 is an important regulator of osteoblast proliferation.
Specifically, two siRNA, specific for Tbx3, knocked down expression of Tbx3 and Tbx3 siRNA reduced basal-and serum-induced osteoblast cell proliferation, but did not increase cell apoptosis. Similar findings have been observed in rat bladder carcinoma cells (22 
